Fig 1.
Clinical presentation of the patients at baseline and with brentuximab vedotin treatment. (A) 66-year-old woman with mycosis fungoides (MF) stage IVB with oral disease; the patient had a maximum reduction in modified Severity-Weighted Assessment Tool score from time of screening (mSWATmax) of 86%. (B) 87-year-old man with MF stage IIB with ulcerative tumor on the arm; the patient had an mSWATmax reduction of 92%. (C) 66-year-old man with MF stage IIB with forehead tumor; the patient had an mSWATmax reduction of 97%. (D) 78-year-old woman with Sézary syndrome (SS) stage IVA1; the patient had an mSWATmax reduction of 100% (global complete response). (E) 80-year-old woman with SS stage IVA1; the patient had an mSWATmax reduction of 89%; flow cytometry showing reduction of CD4+/CD26-/CD30+ Sézary population after treatment. (F) 45-year-old man with MF IVA2 with reduction in lymph-node disease after treatment, as shown in the positron emission tomography-computed tomography scan.